Older drugs aren’t just cheaper, they’re better, study says

Tracy Staton Generic drugs already have cost on their side when competing with pricey brands. But according to a new study in Health Affairs, older meds may actually be more effective, ...

KV rebounds as docs get uneasy about compounded drugs

Eric Palmer The compounding pharmacy problems that have been so hard on patients and landed the FDA in the doghouse have been a savior for at least one company, KV Pharmaceutical, and ...

Clovis soars on upbeat signs of efficacy for targeted cancer drugs

John Carroll FierceBiotech News

ASCO confab highlights immunotherapies, ‘breakthrough’ drugs and small victories

John Carroll CHICAGO–The showdown between Bristol-Myers Squibb ($ BMY) and Merck ($ MRK) over a new PD-1 approach to spurring an immune response to cancer didn't disappoint. FierceBiotech ...

EMA backs approval of key drugs from Celgene and Aegerion

Ryan McBride Two drugmakers reported regulatory victories for therapies in the important European market. A European Medicines Agency committee endorsed approval of Celgene's ($ ...

Rebellious FDA Reviewer Insists ARB Heart Drugs Have Cancer Risk

esilverman Yet another instance of an FDA medical reviewer clashing with agency supervisors is playing out over a group of drugs called angiotension receptor blockers, which ...

Top 10 experimental cancer drugs – 2013

Alok Saboo In our third annual report on 10 exciting cancer drugs, there are plenty of R&D programs zipping through trials with the blessing of the FDA, which has awarded "breakthrough" ...

GlaxoSmithKline nabs key FDA approvals for two melanoma drugs

Tracy Staton Two of GlaxoSmithKline's hopes for 2013 are now fulfilled: The company won FDA approval for its melanoma treatments Tafinlar and Mekinist, both targeted at patients ...

GlaxoSmithKline gains FDA OK on two genetically targeted skin cancer drugs

John Carroll In an important win for GlaxoSmithKline's R&D division, the FDA today announced that it has approved a pair of genetically targeted melanoma drugs, dabrafenib and ...

Consumer Reports warns against fast-growing use of testosterone drugs

Tracy Staton Consumer Reports has weighed in on the rising use of testosterone drugs, which added some $ 2 billion to drugmakers' coffers last year. If patients listen to the magazine, ...

Merck marks another failure in elusive hunt for Parkinson’s disease drugs

Ryan McBride Merck has cut one of most advanced efforts to develop a new therapy for Parkinson's disease. Its Phase III clinical trials of preladenant for the prevalent neurological ...

Specialty drugs to rocket upward by 67% by 2015

Tracy Staton Drugmakers know that specialty products are where it's at these days. A recent IMS Institute report showed the U.S. drug market shrinking for the first time last year. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS